Prothena Corporation plc (PRTA) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $8.64
• Market Cap: $478.01M
• EPS: $-5.20
• 52-Week High: $16.16
• 52-Week Low: $4.32

Market Sentiment

Prothena Corporation plc currently has a Neutral sentiment score of 0.14.

About Prothena Corporation plc

Prothena Corporation plc is a clinical-stage biotechnology company based in Dublin, Ireland, focused on the discovery and development of innovative therapies for severe, life-threatening diseases. With a robust pipeline aimed at addressing disorders linked to protein misfolding, including Alzheimer's disease and other neurodegenerative conditions, Prothena is dedicated to meeting substantial unmet medical needs. Leveraging state-of-the-art scientific research and a strong portfolio of intelle...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Prothena Corporation plc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does PRTA pay dividends?

Prothena Corporation plc (PRTA) does not currently pay a regular dividend.

What is PRTA's market cap?

Prothena Corporation plc (PRTA) has a market capitalization of $478.01M with a current stock price of $8.64.